Non-Hodgkin Lymphoma - Pipeline Review, H1 2017 provides Comprehensive Information on the Therapeutics under Development

ResearchMoz added Latest Research Report titled " Non-Hodgkin Lymphoma - Pipeline Review, H1 2017 " to it's Large Report database.

Non-Hodgkin Lymphoma - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.

Non-Hodgkin lymphoma (also known as non-Hodgkin lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the bodys immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing.Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1135786

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 28, 137, 124, 5, 123, 18 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 15, 17, 16 and 4 molecules, respectively.

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

Table of Contents 2
Introduction 11
Non-Hodgkin Lymphoma - Overview 12
Non-Hodgkin Lymphoma - Therapeutics Development 13
Non-Hodgkin Lymphoma - Therapeutics Assessment 85
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 111
Non-Hodgkin Lymphoma - Drug Profiles 233
Non-Hodgkin Lymphoma - Dormant Projects 1656
Non-Hodgkin Lymphoma - Discontinued Products 1676
Non-Hodgkin Lymphoma - Product Development Milestones 1684
Appendix 1692

List of Tables
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2017 60
Number of Products under Development by Companies, H1 2017 62
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 63
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 64
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 65
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 66
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 67
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 68
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 69
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 70

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

Non-Hodgkin Lymphoma Market Research Report - Heat Map and Analysis: Development Trend and Future Forecast

ResearchMoz added Latest Research Report titled " Non-Hodgkin Lymphoma - Heat Map and Analysis " to it's Large Report database.

Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing) or aggressive (fast-growing). Almost 85% of NHLs are of B-cell origin, while 15% are derived from T/natural killer cells. The small remainder stem from macrophages. Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the two most common types of NHL, representing over 50% of cases.

The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heat map framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed readouts of all late-stage clinical trial results for products in the NHL market and Phase III pipeline. These are split along lines of therapy, and so are reflective of the treatment algorithm used in the clinic.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=970723

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

• How is the NHL market landscape expected to change with the uptake of promising novel pipeline products and products that have been recently approved?
• What are the clinical characteristics of currently approved therapies for NHL, in terms of specific safety and efficacy parameters?
• What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?
• What treatment line settings have the greatest unmet need for pipeline drugs to fill?
• Which pipeline drugs have shown the strongest efficacy in clinical trials, and how do these compare to clinical trials of currently marketed drugs?

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents
1 Table of Contents 2

2 Introduction 3
2.1 Report Guidance 4

3 Marketed Products 5
3.1 Overview 5
3.2 Remission Induction Therapy 5
3.3 Maintenance Therapy 6
3.4 Post-Relapse Treatment 6

4 Pipeline Products 8
4.1 Changes to Induction Therapy, 2015–2022 8
4.2 Changes to Post-Relapse Treatment, 2015–2022 8

5 Appendix 10
5.1 Abbreviations 10
5.2 References 10
5.3 Research Methodology 14
5.4 Contact Us 14
5.5 Disclaimer 15

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG